In a report released on September 5, Asthika Goonewardene from Truist Financial maintained a Hold rating on Mersana Therapeutics (MRSN – Research Report). The company’s shares closed yesterday at $1.23.
Goonewardene covers the Healthcare sector, focusing on stocks such as Mersana Therapeutics, Genmab, and Compugen. According to TipRanks, Goonewardene has an average return of -17.3% and a 28.87% success rate on recommended stocks.
The word on The Street in general, suggests a Hold analyst consensus rating for Mersana Therapeutics with a $1.33 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Mersana Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $10.65 million and a GAAP net loss of $54.3 million. In comparison, last year the company earned a revenue of $4.28 million and had a GAAP net loss of $52.2 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Mersana Therapeutics, Inc. engages in the development and manufacture of antibody drug conjugates to improve patient outcomes in multiple oncology indications. Its lead product candidates are XMT-1522, which focuses on breast cancer and non-small cell lung cancer (NSCLC); and XMT-1536, which targets ovarian cancer and NSCLC. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.
Read More on MRSN:
